Dainippon Of Japan Seeks Approval For First-Line Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma has applied for approval of a reformulated version of metformin, a diabetes drug. Dainippon wants to sell its SMP-862 drug in a larger dose as the primary treatment for Type 2 diabetes. Metformin itself was approved in Japan in 1961 as Melbin, but has been approved only as a second-line treatment in case other drugs fail to work. The company is relying on foreign trials rather than conducting new trials, because it licensed the drug from Merck Sante. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.